[PDF] Drug Shortage Mitigation Through Supply Chain Management eBook
Drug Shortage Mitigation Through Supply Chain Management Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Drug Shortage Mitigation Through Supply Chain Management book. This book definitely worth reading, it is an incredibly well-written.
Scientific Essay from the year 2013 in the subject Business economics - Supply, Production, Logistics, grade: 1,0, San Diego State University, course: Global Supply Chain Management, language: English, abstract: The healthcare system of the U.S. is increasingly challenged by prescription drug shortages. But what are the root causes for this problem and how can these shortages be mitigated? Which role plays effective supply chain management in that setting? This paper addresses these questions and discusses possible approaches to strengthen the pharmaceutical supply chain in the U.S.
This book provides an insight of relevant case studies and updated practices in “PharmaceuticalSupply Chains” (PharmSC) while addressing the most relevant topics within the COST Action “Medicines Shortages” (CA15105).The volume focuses on the most recent developments in the design, planning and scheduling ofPharmSC, broadening from the suppliers’ selection to the impact on patients and healthcaresystems, addressing uncertainty and risk mitigation, and computational issues. It is directed at MSc/PhD students and young researchers (Post-Docs) in Pharmaceutics/Pharmaceutical sciences, Engineering fields, Economics/Management, as well as pharmaceutical decision makers, managers, and practitioners, and advanced readers demanding a fresh approach to decision making for PharmSC. The contributed chapters are associated with the homonymous COST Training Schools (TS), and the book creates a better understanding of the Action “Medicines Shortages” challenges and opportunities.
"This publication covers both strategic and operational level elements of logistics and supply chain research, providing a comprehensive overview of the field with particular attention to new technologies, digitization, and optimization as applied in the era of globalized business"--
This book provides an insight of relevant case studies and updated practices in "Pharmaceutical Supply Chains" (PharmSC) while addressing the most relevant topics within the COST Action "Medicines Shortages" (CA15105). The volume focuses on the most recent developments in the design, planning and scheduling of PharmSC, broadening from the suppliers' selection to the impact on patients and healthcare systems, addressing uncertainty and risk mitigation, and computational issues. It is directed at MSc/PhD students and young researchers (Post-Docs) in Pharmaceutics/Pharmaceutical sciences, Engineering fields, Economics/Management, as well as pharmaceutical decision makers, managers, and practitioners, and advanced readers demanding a fresh approach to decision making for PharmSC. The contributed chapters are associated with the homonymous COST Training Schools (TS), and the book creates a better understanding of the Action "Medicines Shortages" challenges and opportunities.
“Supply Chain Risk Management is an issue that many companies face and yet few companies know how to deal with it in a systematic and pragmatic manner. While avoiding and reducing supply chain risks are certainly preferable, developing ways to restore and stabilize supply chain operations rapidly after a major disruption is critical for managing global supply chains. Sodhi and Tang present important concepts, frameworks, strategies, and analyses that are essential for managing supply chain risks. Not only does this book suggest some practical ways to work with different partners to manage the risks that are present in a global supply chain, it creates a framework that would enable practitioners to engage researchers to work on this important area.” —Thomas A. Debrowski, Executive Vice President, Worldwide Operations, Mattel, Inc. “When a firm outsources its operations to external suppliers, the firm is vulnerable to major and rare disruptions that can occur at any link in the global supply chain. Because these disruptions rarely occur, few firms take commensurable actions to identify, assess, mitigate and respond to various types of supply chain risks. By introducing frameworks and concepts along with several case studies and a review of academic literature, Sodhi and Tang treat this important subject with practical relevance and academic rigor. This book will bring practitioners and researchers to develop effective and efficient ways to manage supply chain risks.” —Marshall L. Fisher, UPS Professor, Professor of Operations and Information Management and Co-Director of Fishman-Davidson Center for Service and Operations Management, The Wharton School, University of Pennsylvania “This book ties observations in practice to methodologies and research. The rich case examples motivated the approaches and methodologies used to mitigate risks, and in the course of doing so, Sodhi and Tang provided insights on existing and new research opportunities. As a result, this book is highly relevant to both practitioners and academics. Also, the book is also written with management lessons on how risks can be mitigated, and how risks can be contained once disruptions have occurred. As such, it is also a book for management to gain insights and to develop management skills.” —Hau L. Lee, Thoma Professor of Operations, Information and Technology and Director of the Stanford Global Supply Chain Management Forum, Graduate School of Business, Stanford University “As companies have extended their supply chains globally and as the face increasing resource issues, they face a number of new risk challenges. While there are various case studies written about supply chain risks, this book gives a comprehensive treatment of the subject with clarity. The concepts and frameworks developed by Sodhi and Tang in this book would create awareness of this important and yet not well understood subject, and strategies described in this book would stimulate practitioners to develop a holistic approach for identifying, assessing, mitigating, and responding to different types of supply chain risks.” —Nick Wildgoose, Global Supply Chain Proposition Manager, Zurich Insurance
Why does management science help organizations to avoid/solve resource shortage?Because management is a core function of every business and a number of theories try to explain how any why resource will be use rapidly and resource shortage causes to any organization. The core function of the management science approach is to compare possible outcomes. In addition, managers in various functions have aware of the potential contribution of analytical modes . So, the managerical science function involves arranging equipment perform functions, such as procurement, production etc. activities.For drug manufacturing organization or hospital, clinic, medical service organizations exmaple, any kinds of drug must be important resource to provide patients to eat. If they have not enough drugs to be provided to the hospital, clinic, medical service organizational patients to eat. Then, their sicknesses may become serious suddenly. So, managing enough drugs stick is very important. However, management science may help any one these medical organization to implement rationality in strategic decisions: Choice which kinds of drugs purchase number, in order to keep enough drugs supply in drug store room. Understanding in a drug resource pool choice, due to cash available is limited to any one medical organizations. Management science aims to avoid drug shortage to any one medical organizations. Such as this drug organization case, management science may help them to identify the processes, which kinds of drugs are needed to buy immediately, notice the areas of weaknesses, and realize the future possibilities and needs of the medical organization's patient customers needs. The approach makes the drug utilization of resources easier, since the framework can notice the availability of drug resources and the proper eat of them to be provided to any sickness kinds of patients to eat immediately when the medical organization can have enough drug stocks supply.How to apply management science to help hospital better prepare for a drug shortage management method may include: Having a plan, the director of pharmacy should consider developing a plan for managing drug shortages, implement structured communications. Ask the right questions, instead of, hospital management also needs to know what is causing drug shortages. IN fact, drug shortages are caused by many factors, including: regulatory issues, and business decisions as well as many other disturbances within the supply chain.Hence, in management science view point, hospital can attempt to apply mobile App technolgies tool to solve drug shortage problem, because mobile App technologies tool can be one kind of immediate communication tool, it can identify when the kind of drug will shortage and their impact on hospitals, e.g. how many the kind of sickness patient number and automates the entire life cycle of managing any kinds of drug shortage. Mobile App, communication technologic tool can provide clinical information that allows teams to understand and mitigate the ramifications for shorted medications. Any possible drug shortage solution in hoepital, it may be a management strategy that includes clear policies and producers for information. It defines a drug shortage is as a supply issue that affects how the drug store room's daily drug supplies.Thus, management science may help any medical organizations to solve drug shortage crisis, it may help any organizations to attempt to reduce health care cost, one common solution for mitigating shortages is to keep more drug inventory, but drug inventory number can not be excess, in order to avoid drug out of patients ( old drug) to let patients to eat in difficult. Hence, any medical organizations need to implement good pharmaceutical supply chain management strategy in order to solve drug resolve shortage challenge causes.
Abstract: Drug shortage is a worldwide problem, which gained the attention of many authorities in recent years including the Egyptian government. The problem has markedly increased in Egypt during the past few years and has had a significant negative impact on patient care with subsequent costly financial implications. Despite the importance of the drug shortage problem and its consequences on the health of Egyptians and society as a whole, only a few researchers have addressed the topic in Egypt. This qualitative study aims at filling the gap and providing a better understanding of the problem in the Egyptian context. To achieve the study objective, the root causes of the problem and the actions taken by the government to mitigate the problem are explored. In-depth, semi-structured interviews are carried out with different stakeholders including from government, industry, distributors, and pharmacies. The findings of this research revealed that the drug shortage is attributed to a myriad of interlinked causes. The most critical causes of drug shortages are as follows: the drug pricing constraints, the devaluation, economic changes, overdependence on the importation of production inputs, illegal distribution practices, excessive bureaucracy and complicated procedures, manufacturing problems, poor supply chain management, and scarcity of raw materials. The findings also show that although the government has exerted many efforts to tackle drug shortages, there is still a gap to be addressed. Based on experiences of other countries and according to the Egyptian context, solutions are proposed to help in mitigating drug shortages in Egypt which include enhancing the sustainability of the production of medicines by improving companies’ profitability, improving collaboration between various stakeholders, developing a system for reporting and communication of drug shortage information, and modifying workflow within MoHP to avoid unnecessary delays.
This report offers insights into the risks and vulnerabilities of the supply chains of medicines and medical devices. Policy options to anticipate and mitigate risks of shortages of medicines and medical devices, both routinely and in the context of severe crises, are analysed. Most importantly, the report shows that strengthening the long-term resilience of medical supply chains requires collaborative approaches that balance measures best undertaken by the private sector with those more appropriately managed by governments or supranationally.
National Academies of Sciences, Engineering, and Medicine
Author : National Academies of Sciences, Engineering, and Medicine Publisher : National Academies Press Page : 235 pages File Size : 36,24 MB Release : 2018-03-01 Category : Medical ISBN : 0309468086
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : Institute of Medicine Publisher : National Academies Press Page : 377 pages File Size : 25,29 MB Release : 2013-06-20 Category : Medical ISBN : 0309269393
The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.